MedeliX
Start asking

finerenone

Kerendia · ATC code C09

Also known as: Finerenon

Key facts
Active substance
finerenone
ATC code
C09
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Kerendia 10 mg film-coated tablets / Kerendia 20 mg film-coated tablets / Kerendia 40 mg film-coated tablets
Marketing authorisation holder
Bayer AG
Information as of
2026-10-27

Key facts

Finerenone (Kerendia) is a non-steroidal mineralocorticoid receptor antagonist for chronic kidney disease associated with type 2 diabetes and symptomatic chronic heart failure with LVEF ≥ 40% in adults.

What it is used for

  • Chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults
  • Symptomatic chronic heart failure with LVEF ≥ 40% in adults

Dosing

  • CKD with type 2 diabetes: target and maximum dose 20 mg once daily; start 20 mg if eGFR ≥ 60, 10 mg if eGFR ≥ 25 to < 60; not recommended if eGFR < 25
  • Heart failure: target dose 40 mg once daily if eGFR ≥ 60, or 20 mg if eGFR ≥ 25 to < 60; maximum 40 mg
  • Start only if serum potassium ≤ 5.0 mmol/L; remeasure potassium and eGFR 4 weeks after start or dose change
  • Withhold if potassium > 5.5 mmol/L; restart at 10 mg once ≤ 5.0 mmol/L
  • Do not initiate in severe hepatic impairment; further adjustment steps in the full text

Contraindications

  • Hypersensitivity to the active substance or any excipient
  • Concomitant strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin)
  • Addison's disease

Important warnings

  • Hyperkalaemia; higher risk with low eGFR, higher potassium or previous hyperkalaemia – more frequent monitoring
  • Caution and potassium monitoring with potassium supplements, potassium-enriched salt substitutes or trimethoprim
  • Heart failure: increased incidence of worsening renal function
  • No grapefruit or grapefruit juice during treatment

Side effects

  • Most frequent: hyperkalaemia
  • Common: hyponatraemia, hyperuricaemia, hypotension, pruritus, increased creatinine/decreased GFR
  • In heart failure also common: diarrhoea, constipation, renal impairment, acute kidney injury

Interactions

  • Strong CYP3A4 inhibitors: contraindicated (marked increase in exposure)
  • Strong and moderate CYP3A4 inducers (e.g. rifampicin, carbamazepine, St John's Wort, efavirenz): not recommended
  • Potassium supplements, trimethoprim: monitor potassium, temporary discontinuation may be needed

Pregnancy and breastfeeding

  • Women of childbearing potential should use effective contraception; use in pregnancy only if the clinical condition requires it

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Brand names in 3 more European countries
Iceland
Kerendia
Liechtenstein
Kerendia
Norway
Kerendia

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Kerendia – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_en.pdf

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.